An open-label, controlled trial of the efficacy and safety of Laennec to improve liver function in patients with non-alcoholic fatty liver disease
Author:
Affiliation:
1. Military Hospital No. 103 of the Republic of Vietnam
2. Federal Research Center “Computer Science and Control” of the Russian Academy of Sciences
Publisher
LLC Global Media Technology
Subject
Gastroenterology,Hepatology
Reference17 articles.
1. Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020 Dec 14;134(1):8-19. doi: 10.1097/CM9.0000000000001263.
2. Ivashkin V. T., Maevskaya M. V., Pavlov Ch.S. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association.Russian journal of gastroenterology, hepatology, coloproctology. 2016;26(2):24-42. (in Russ.) doi: 10.22416/1382-4376-2016-26-2-24-42.@@ Ivashkin VT, Maevskaya MV, Pavlov ChS, Tikhonov IN, Shirokova EN, Bueverov AO, Drapkina OM, Shul'pekova YuO, Tsukanov VV, Mammaev SN, Maev IV, Pal'gova LK. Klinicheskie rekomendatsii po diagnostike i lecheniyu nealkogol'noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniyu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2016;26(2):24-42. doi: 10.22416/1382-4376-2016-26-2-24-42.
3. Estes C., Anstee Q. M., Arias-Loste M.T., Bantel H., Bellentani S. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain and other countries for the period 2016-2030. J Hepatol. 2018;69(4):896-904. doi: 10.16/j.jhep.2018.05.036.
4. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298.
5. Fujii H., Kawada N., JapanStudyGroupOfNafldJsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.Int J Mol Sci. 2020 May 29;21(11):3863. doi: 10.3390/ijms21113863.
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy of human placenta hydrolyzate in the treatment of patients with metabolic associated fatty liver disease at the stage of fibrosis (pilot study);Terapevticheskii arkhiv;2024-03-30
2. Systematic analysis of the pharmacology of standardized extracts of human placenta;Pharmacokinetics and Pharmacodynamics;2024-01-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3